Clinical Approach to Menstrual Change
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of menstrual change
Menstrual changes represent one of the most common presenting complaints in primary care and gynecology, affecting approximately 10 to 30 percent of reproductive-age women at some point in their lives. Abnormal uterine bleeding accounts for nearly one-third of all gynecology outpatient visits and is responsible for significant healthcare utilization, with an estimated 600,000 hysterectomies performed annually in the United States, of which approximately 50 percent are for abnormal bleeding. Beyond the clinical burden, menstrual changes profoundly impact quality of life, work productivity, and psychological well-being.
Definition
Menstrual change refers to any deviation from the patient’s established normal menstrual pattern or from the physiological norms for menstruation. This encompasses alterations in cycle frequency, regularity, duration of flow, and volume of blood loss. A normal menstrual cycle occurs every 24 to 38 days, with bleeding lasting 4 to 8 days and blood loss of 5 to 80 milliliters per cycle.
Normal Menstrual Parameters (FIGO 2018)
- Cycle frequency: 24 to 38 days
- Cycle regularity: Variation of ± 7 to 9 days
- Duration of flow: Up to 8 days
- Volume of flow: 5 to 80 mL per cycle
- Intermenstrual bleeding: Absent
- Menarche to regularity: 1 to 2 years
Classification by Cycle Frequency
| Category | Cycle Length | Common Causes | Clinical Significance |
|---|---|---|---|
| Frequent menstruation | Less than 24 days | Ovulatory dysfunction, luteal phase defect, perimenopause | May indicate anovulation; assess for anemia |
| Normal frequency | 24 to 38 days | Physiological variation | Normal range; reassurance appropriate |
| Infrequent menstruation | Greater than 38 days | Polycystic ovary syndrome, hypothalamic dysfunction, hyperprolactinemia | Evaluate for anovulation and endometrial protection |
| Amenorrhea | Absent for 3+ months (or 6+ months if previously irregular) | Pregnancy, hypothalamic amenorrhea, premature ovarian insufficiency | Always exclude pregnancy; assess estrogen status |
Classification by Volume of Menstrual Blood Loss
Heavy Menstrual Bleeding
Definition: Excessive menstrual blood loss that interferes with physical, social, emotional, or material quality of life. Historically defined as greater than 80 mL per cycle, but now based on patient perception.
Clinical clues: Soaking through protection hourly, passing clots larger than a coin, double protection needed, significant impact on daily activities.
Light Menstrual Bleeding
Definition: Menstrual blood loss that is noticeably reduced from the patient’s normal pattern or is less than 5 mL per cycle.
Clinical clues: Minimal spotting only, no need for regular protection, significantly shorter duration than previous cycles.
Classification by Duration of Flow
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Normal duration | 4 to 8 days | Physiological | Reassurance appropriate |
| Prolonged bleeding | Greater than 8 days | Fibroids, adenomyosis, coagulopathy, endometrial polyps | Increases risk of anemia; evaluate for structural causes |
| Shortened bleeding | Less than 4 days | Hormonal contraception, Asherman syndrome, low estrogen states | May reflect thin endometrium or outlet obstruction |
Classification by Pattern and Timing
| Pattern | Description | Suggests |
|---|---|---|
| Regular cycles with heavy flow | Predictable timing but excessive volume | Structural causes: fibroids, adenomyosis, coagulopathy |
| Irregular unpredictable cycles | Variable timing with variable flow | Ovulatory dysfunction, polycystic ovary syndrome, perimenopause |
| Intermenstrual bleeding | Bleeding between expected menstrual periods | Endometrial polyps, cervical pathology, hormonal contraception breakthrough |
| Postcoital bleeding | Bleeding after intercourse | Cervical ectropion, cervicitis, cervical polyps, cervical malignancy |
| Postmenopausal bleeding | Any bleeding after 12 months of amenorrhea in menopause | Endometrial atrophy, polyps, hyperplasia, malignancy — always investigate |
The PALM-COEIN Classification System (FIGO)
Key Concept: The International Federation of Gynecology and Obstetrics (FIGO) developed the PALM-COEIN system to standardize the classification of abnormal uterine bleeding causes. PALM represents structural causes (visible on imaging or histopathology), while COEIN represents non-structural causes.
PALM (Structural Causes)
- P — Polyp (endometrial or cervical)
- A — Adenomyosis
- L — Leiomyoma (fibroids)
- M — Malignancy and hyperplasia
COEIN (Non-Structural Causes)
- C — Coagulopathy
- O — Ovulatory dysfunction
- E — Endometrial causes
- I — Iatrogenic
- N — Not yet classified
Age-Related Considerations
| Age Group | Most Common Causes | Key Considerations |
|---|---|---|
| Adolescents (menarche to 19 years) | Anovulatory cycles (immature hypothalamic-pituitary-ovarian axis), coagulopathy, pregnancy | Up to 20% with heavy bleeding have underlying bleeding disorder; allow 2 years for cycle maturation |
| Reproductive age (20 to 39 years) | Pregnancy-related, structural lesions (fibroids, polyps), ovulatory dysfunction | Always exclude pregnancy first; structural causes become more prevalent |
| Perimenopause (40 to menopause) | Ovulatory dysfunction, structural lesions, endometrial hyperplasia | Lower threshold for endometrial sampling; malignancy risk increases |
| Postmenopause | Endometrial atrophy (60-80%), polyps, hyperplasia, malignancy | All postmenopausal bleeding requires investigation to exclude malignancy |
Impact on Quality of Life
Menstrual changes significantly affect women’s daily functioning:
- Physical: Iron deficiency anemia (affects up to 60% with heavy menstrual bleeding), fatigue, exercise intolerance
- Social: Activity restriction, embarrassment, social isolation during menses
- Economic: Work absenteeism (estimated 23 million work days lost annually), healthcare costs
- Psychological: Anxiety, depression, reduced self-esteem, fertility concerns
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of menstrual change
Understanding the physiology of normal menstruation is essential for diagnosing and managing menstrual changes. The menstrual cycle represents a complex interplay between the hypothalamus, pituitary gland, ovaries, and uterus, coordinated through precisely timed hormonal signals. Disruption at any level of this axis, or within the end organ itself, can result in abnormal menstrual patterns.
The Hypothalamic-Pituitary-Ovarian Axis
| Component | Structure | Hormones | Function |
|---|---|---|---|
| Hypothalamus | Arcuate nucleus, median eminence | Gonadotropin-releasing hormone (GnRH) | Pulsatile GnRH release controls pituitary gonadotropin secretion |
| Anterior Pituitary | Gonadotroph cells | Follicle-stimulating hormone (FSH), Luteinizing hormone (LH) | FSH stimulates follicular development; LH triggers ovulation and corpus luteum formation |
| Ovaries | Follicles, corpus luteum, stroma | Estrogen, progesterone, inhibin, androgens | Produce steroid hormones that regulate endometrium and provide feedback |
| Uterus | Endometrium (functional and basal layers) | Responds to estrogen and progesterone | End organ: proliferates, secretes, and sheds in response to hormonal signals |
Phases of the Menstrual Cycle
Follicular Phase (Days 1-14)
Ovarian events: FSH recruits follicles; one dominant follicle emerges, producing increasing estrogen.
Endometrial events: Estrogen drives proliferation of the endometrium (proliferative phase).
Clinical relevance: Variable length accounts for most cycle-to-cycle variation.
Ovulation (Day 14)
Ovarian events: LH surge triggers release of mature oocyte from dominant follicle.
Endometrial events: Transition from proliferative to secretory phase begins.
Clinical relevance: Anovulation is the most common cause of irregular cycles.
Luteal Phase (Days 15-28)
Ovarian events: Corpus luteum produces progesterone and estrogen for approximately 14 days.
Endometrial events: Progesterone transforms endometrium to secretory phase, preparing for implantation.
Clinical relevance: Relatively fixed duration; luteal phase defect causes short cycles.
Mechanism of Menstruation
The Trigger: If pregnancy does not occur, the corpus luteum regresses, causing a rapid decline in progesterone and estrogen levels. This hormone withdrawal initiates a cascade of events leading to menstruation.
| Step | Event | Mechanism |
|---|---|---|
| 1. Hormone withdrawal | Corpus luteum regression | Progesterone and estrogen levels fall sharply |
| 2. Vasoconstriction | Spiral arteriole spasm | Prostaglandins and endothelins cause intense vasoconstriction |
| 3. Ischemia | Tissue hypoxia | Functional layer becomes ischemic due to reduced blood flow |
| 4. Tissue breakdown | Matrix metalloproteinase activation | Enzymes break down extracellular matrix, releasing the functional layer |
| 5. Hemostasis | Clot formation and vasoconstriction | Local hemostatic mechanisms limit blood loss; re-epithelialization begins from basal layer |
How Different Conditions Cause Menstrual Changes
Structural Causes (PALM)
| Condition | Mechanism of Abnormal Bleeding | Treatment Implication |
|---|---|---|
| Endometrial polyps | Localized overgrowths with fragile vessels and irregular surface epithelium prone to breakdown; may interfere with hemostatic mechanisms | Hysteroscopic polypectomy provides definitive treatment |
| Adenomyosis | Ectopic endometrial glands within myometrium cause uterine enlargement, increased surface area, and impaired myometrial contractility needed for hemostasis | Hormonal suppression or hysterectomy for definitive treatment |
| Leiomyomas (fibroids) | Submucosal fibroids distort endometrial cavity, increase surface area, compress vessels causing venous ectasia, and may impair hemostatic plug formation | Location determines symptoms; submucosal fibroids most likely to cause bleeding |
| Endometrial malignancy and hyperplasia | Abnormal tissue with friable, irregular vessels; loss of normal stromal-epithelial organization; neovascularization with fragile vessels | Requires histological diagnosis and staging; definitive surgical management |
Non-Structural Causes (COEIN)
| Condition | Mechanism of Abnormal Bleeding | Treatment Implication |
|---|---|---|
| Coagulopathy | Impaired platelet function or coagulation cascade leads to failure of normal hemostatic mechanisms at sites of endometrial vessel exposure | Treat underlying disorder; antifibrinolytics helpful adjuncts |
| Ovulatory dysfunction | Anovulation leads to unopposed estrogen stimulation, causing irregular endometrial proliferation, unstable tissue, and unpredictable shedding without progesterone-mediated organization | Restore regular cycles with progestins or combined hormonal contraceptives |
| Endometrial causes | Primary disorders of endometrial hemostasis, inflammation, or repair mechanisms independent of structural or hormonal abnormalities | Often diagnosis of exclusion; may respond to local therapies |
| Iatrogenic | Hormonal contraceptives cause endometrial atrophy with fragile vessels; anticoagulants impair hemostasis; intrauterine devices may cause local inflammation | Modify or discontinue causative agent if possible |
Anovulation: The Most Common Mechanism
Understanding Anovulatory Bleeding
Anovulation is the single most common cause of abnormal uterine bleeding in reproductive-age women. Without ovulation, no corpus luteum forms, and therefore no progesterone is produced.
- Unopposed estrogen: Continuous estrogen stimulation causes the endometrium to proliferate excessively
- Unstable endometrium: Without progesterone to organize and stabilize, the endometrium becomes fragile and unstable
- Irregular shedding: Random breakdown occurs when endometrium outgrows its blood supply or estrogen levels fluctuate
- Unpredictable pattern: Bleeding is typically irregular in timing, duration, and volume
Common Causes of Anovulatory Cycles
Physiological Anovulation
- Adolescence: Immature hypothalamic-pituitary-ovarian axis (normal for first 1-2 years after menarche)
- Perimenopause: Declining ovarian reserve with erratic follicular development
- Lactation: Prolactin suppresses GnRH pulsatility
- Postpartum: Temporary hypothalamic-pituitary-ovarian axis suppression
Pathological Anovulation
- Polycystic ovary syndrome: Hyperandrogenism disrupts follicular development
- Hypothalamic amenorrhea: Low energy availability, stress, or excessive exercise suppress GnRH
- Hyperprolactinemia: Elevated prolactin inhibits GnRH
- Thyroid dysfunction: Both hypo- and hyperthyroidism disrupt the axis
- Premature ovarian insufficiency: Depleted follicular reserve
Often Overlooked Mechanism: Coagulopathy in Adolescents
Up to 20 percent of adolescents presenting with heavy menstrual bleeding at menarche have an underlying bleeding disorder, most commonly von Willebrand disease. This is frequently missed because the bleeding disorder becomes clinically apparent only with the hemostatic challenge of menstruation. Any adolescent with heavy menstrual bleeding from menarche, especially with a family history of bleeding or personal history of easy bruising, epistaxis, or bleeding with dental procedures, should be evaluated for coagulopathy.
Endometrial Hemostasis: Why Bleeding Stops
| Mechanism | Description | When Disrupted |
|---|---|---|
| Vasoconstriction | Spiral arterioles constrict in response to prostaglandins and local factors | Enlarged uterus (fibroids, adenomyosis) impairs myometrial contraction |
| Platelet plug formation | Platelets aggregate at sites of vessel exposure | Thrombocytopenia, platelet dysfunction, von Willebrand disease |
| Coagulation cascade | Fibrin clot reinforces platelet plug | Coagulation factor deficiencies, anticoagulant medications |
| Fibrinolysis regulation | Balance between clot formation and breakdown | Excessive fibrinolysis leads to clot dissolution and continued bleeding |
| Re-epithelialization | Rapid regeneration from basal layer restores surface integrity | Impaired in Asherman syndrome (intrauterine adhesions) |
Key Pathophysiological Concept: Menstrual changes can result from disruption at multiple levels — the hypothalamic-pituitary-ovarian axis (causing ovulatory dysfunction), structural abnormalities of the uterus (fibroids, polyps, adenomyosis), disorders of endometrial hemostasis (coagulopathy, excessive fibrinolysis), or external factors (medications, systemic disease). A thorough evaluation must consider all these mechanisms, and multiple causes may coexist in the same patient.
3. History Taking
A comprehensive approach to eliciting the menstrual change history
Red Flags — Require Urgent Evaluation
- Hemodynamic instability — Tachycardia, hypotension, syncope with active bleeding
- Postmenopausal bleeding — Any bleeding after 12 months of amenorrhea (endometrial cancer until proven otherwise)
- Pregnancy with bleeding — Ectopic pregnancy, miscarriage, molar pregnancy
- Severe anemia symptoms — Dyspnea at rest, chest pain, presyncope
- Rapidly enlarging pelvic mass — Malignancy, degenerating fibroid
- Postcoital bleeding persisting — Cervical pathology including malignancy
- Heavy bleeding with known coagulopathy — May require factor replacement
- New onset heavy bleeding in adolescent — Screen for bleeding disorder (up to 20% have coagulopathy)
The Essential First Question
“Could you be pregnant?” — Pregnancy must be excluded in any reproductive-age woman with menstrual changes before proceeding with further evaluation. A urine or serum beta-hCG should be obtained regardless of the patient’s response, as early pregnancy may not be recognized.
Systematic History: The “PERIODS” Approach
Use the mnemonic “PERIODS” to ensure comprehensive history taking for menstrual changes:
- P — Pattern and Previous normal: What is the current pattern? What was your normal cycle like before? When did it change?
- E — Extent of bleeding: How heavy is the flow? How many pads/tampons? Clots? Flooding? Double protection needed?
- R — Regularity and Rhythm: Are cycles predictable? What is the interval between periods? Any intermenstrual or postcoital bleeding?
- I — Impact on life: How does this affect work, activities, relationships, mood? Any symptoms of anemia?
- O — Obstetric and gynecological history: Pregnancies, deliveries, miscarriages, contraception, sexually transmitted infections, cervical screening
- D — Drugs and medical conditions: Medications (especially hormones, anticoagulants), thyroid disease, bleeding disorders, liver/kidney disease
- S — Sexual and social history: Sexual activity, contraceptive needs, fertility desires, stress, weight changes, exercise, family history
Quantifying Menstrual Blood Loss
Objective measurement of menstrual blood loss is impractical clinically. The following questions help estimate severity:
| Assessment Domain | Questions to Ask | Interpretation |
|---|---|---|
| Product use | “How many pads or tampons do you use on your heaviest day? How often do you change them?” | Soaking through a pad or tampon every 1-2 hours suggests heavy bleeding |
| Clots | “Do you pass blood clots? If so, how large are they?” | Clots larger than a 50-pence coin or grape suggest heavy flow |
| Flooding | “Do you ever experience flooding or accidents where blood soaks through your clothes or bedding?” | Flooding episodes indicate heavy menstrual bleeding |
| Double protection | “Do you need to use both a pad and tampon together, or wear extra protection?” | Need for double protection suggests heavy flow |
| Duration | “How many days does your period last? How many of those are heavy flow days?” | Greater than 8 days total or greater than 5 heavy days is prolonged |
| Impact | “Does your period affect your ability to work, exercise, or carry out daily activities?” | Functional limitation is key criterion for heavy menstrual bleeding |
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Uterine fibroids | Heavy regular periods, pelvic pressure, urinary frequency | “Do you feel pressure in your pelvis, or have to urinate more frequently? Do you feel a mass in your abdomen?” |
| Adenomyosis | Heavy periods with severe dysmenorrhea, diffusely enlarged uterus | “Are your periods very painful? Has the pain worsened over time? Does pain start before bleeding begins?” |
| Endometrial polyps | Intermenstrual bleeding, postmenstrual spotting | “Do you have spotting between periods or after your period should have ended?” |
| Polycystic ovary syndrome | Irregular infrequent periods, acne, hirsutism, weight gain | “Have you noticed increased facial hair, acne, or difficulty with weight? How often do you get your period?” |
| Thyroid dysfunction | Menstrual changes with systemic symptoms | “Have you noticed changes in your weight, energy, temperature tolerance, or bowel habits?” |
| Coagulopathy | Heavy bleeding since menarche, family history, other bleeding symptoms | “Have your periods always been heavy since they started? Do you bruise easily, have frequent nosebleeds, or bleed excessively after dental work?” |
| Hyperprolactinemia | Infrequent or absent periods, galactorrhea, headaches, visual changes | “Have you noticed any milky discharge from your nipples? Any headaches or changes in your vision?” |
| Hypothalamic amenorrhea | Absent periods, low body weight, excessive exercise, stress | “Have you had significant weight loss, dietary restriction, or increased exercise recently? Are you under a lot of stress?” |
| Premature ovarian insufficiency | Irregular then absent periods before age 40, vasomotor symptoms | “Have you experienced hot flashes, night sweats, or vaginal dryness? Is there a family history of early menopause?” |
| Endometrial hyperplasia or cancer | Postmenopausal bleeding, persistent intermenstrual bleeding, risk factors | “Have you had any bleeding since your menopause? Do you have diabetes, obesity, or have you ever taken estrogen without progesterone?” |
Essential Obstetric and Gynecological History
Obstetric History
- Gravidity and parity: Number of pregnancies and outcomes
- Pregnancy complications: Postpartum hemorrhage, retained products, uterine instrumentation
- Current pregnancy status: Last menstrual period, possibility of pregnancy
- Fertility desires: Impact on management decisions
- Breastfeeding: Lactational amenorrhea
Gynecological History
- Age at menarche: Establishes baseline
- Previous menstrual pattern: Define what was normal for this patient
- Cervical screening history: Last Pap smear and results
- Sexually transmitted infection history: Particularly chlamydia, gonorrhea
- Previous gynecological procedures: Dilation and curettage, ablation, surgery
Medication and Contraceptive History
Medications That Cause Menstrual Changes
- Anticoagulants — Warfarin, direct oral anticoagulants, heparin increase bleeding
- Antiplatelet agents — Aspirin, clopidogrel impair hemostasis
- Antipsychotics — Risperidone, haloperidol cause hyperprolactinemia
- Antidepressants — SSRIs may increase bleeding risk
- Corticosteroids — Long-term use disrupts the hypothalamic-pituitary-ovarian axis
- Tamoxifen — Increases endometrial polyps and hyperplasia
- Herbal supplements — Ginseng, dong quai, black cohosh may affect bleeding
Contraceptive Effects on Bleeding
- Combined hormonal contraceptives — Usually lighten periods; breakthrough bleeding common initially
- Progestin-only pills — Irregular bleeding, especially in first months
- Depot medroxyprogesterone acetate — Irregular bleeding initially, then often amenorrhea
- Levonorgestrel intrauterine system — Irregular bleeding for 3-6 months, then light or absent periods
- Copper intrauterine device — Heavier, longer, more painful periods (30-50% increase)
- Implant (etonogestrel) — Unpredictable bleeding pattern
Social and Family History
| Domain | What to Ask | Clinical Relevance |
|---|---|---|
| Weight changes | Recent gain or loss, intentional or unintentional | Obesity increases anovulation and endometrial cancer risk; low weight causes hypothalamic amenorrhea |
| Exercise | Type, intensity, frequency of physical activity | Excessive exercise contributes to hypothalamic amenorrhea |
| Stress | Life stressors, psychological state | Chronic stress suppresses hypothalamic-pituitary-ovarian axis function |
| Diet | Restrictive eating, eating disorders | Low energy availability disrupts menstrual function |
| Family history | Bleeding disorders, early menopause, fibroids, gynecological cancers, polycystic ovary syndrome | Genetic predisposition to many causes of menstrual change |
| Sexual history | Sexual activity, partners, contraceptive needs | Determines pregnancy risk, sexually transmitted infection risk, and contraceptive requirements |
Screening Questions for Underlying Bleeding Disorder
Consider coagulopathy if the patient answers “yes” to any of these questions:
- Have your periods been heavy since they first started (menarche)?
- Have you ever been treated for anemia?
- Has a family member been diagnosed with a bleeding disorder?
- Have you ever had significant bleeding after a dental procedure or tooth extraction?
- Have you ever had significant bleeding after surgery?
- Do you have a history of frequent nosebleeds (epistaxis)?
- Do you bruise easily without a clear cause?
- Have you experienced postpartum hemorrhage?
4. Physical Examination
A systematic approach for patients presenting with menstrual change
Systematic Framework: Use a structured approach moving from general assessment through focused pelvic examination. The goal is to identify signs of underlying etiology, assess severity (anemia), and detect red flag findings requiring urgent intervention.
General Inspection
- General appearance: Pallor (anemia), distress, body habitus (obesity as risk factor for anovulation and endometrial pathology)
- Skin: Bruising (coagulopathy), acanthosis nigricans (insulin resistance, polycystic ovary syndrome), hirsutism, acne
- Hair: Hirsutism (hyperandrogenism), hair loss or thinning (thyroid disease, hyperandrogenism)
- Body mass index: Calculate and document — obesity and underweight both affect menstrual function
- Signs of systemic illness: Cachexia, jaundice (liver disease), features of chronic disease
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Heart Rate | Tachycardia at rest (greater than 100 beats per minute) | May indicate significant anemia or acute blood loss; if hypotensive, suggests hypovolemia |
| Blood Pressure | Hypotension, orthostatic changes | Orthostatic hypotension suggests significant volume depletion; assess for acute hemorrhage |
| Temperature | Fever | May indicate pelvic inflammatory disease, infected products of conception, or endometritis |
| Respiratory Rate | Tachypnea at rest | Compensatory response to severe anemia; indicates need for urgent evaluation |
| Oxygen Saturation | Usually preserved unless severe anemia or cardiopulmonary compromise | Document baseline; may be normal even with significant anemia |
Assessment for Anemia
Signs of Chronic Blood Loss
- Conjunctival pallor: Best assessed by everting lower eyelid
- Palmar crease pallor: Creases paler than surrounding skin when hand extended
- Nail bed pallor: Pale nail beds, koilonychia (spoon nails in severe iron deficiency)
- Oral mucosa: Pale gums and tongue
Signs of Severe Anemia
- Tachycardia at rest
- Systolic flow murmur: High-output state
- Bounding pulse
- Ankle edema: In severe cases with high-output heart failure
- Dyspnea at rest or with minimal exertion
Thyroid Examination
- Inspection: Visible goiter, thyroidectomy scar
- Palpation: Thyroid size, nodules, tenderness
- Associated signs of hypothyroidism: Dry skin, periorbital edema, bradycardia, delayed relaxation of reflexes
- Associated signs of hyperthyroidism: Tremor, warm moist skin, tachycardia, lid lag, exophthalmos
Abdominal Examination
Inspection
- Distension: May indicate large fibroid uterus or ascites
- Visible mass: Large fibroids may be visible, especially in thin patients
- Surgical scars: Previous pelvic or abdominal surgery
- Striae: Cushing syndrome (rare cause of menstrual dysfunction)
Palpation
- Uterine enlargement: Palpable above the pubic symphysis if greater than 12-week size; assess size, contour, mobility
- Masses: Location, size, consistency, tenderness, mobility
- Tenderness: Localized or diffuse; rebound or guarding (suggests acute pathology)
- Hepatomegaly: Liver disease affecting coagulation or hormone metabolism
Pelvic Examination
When to Perform Pelvic Examination
Pelvic examination is indicated in most patients with menstrual changes, particularly if:
- Sexually active or history of sexual activity
- Age 21 or older (cervical screening guidelines)
- Suspicion of structural pathology
- Postcoital or intermenstrual bleeding
- Postmenopausal bleeding
It may be deferred in adolescents who have never been sexually active and have a clear explanation for bleeding (such as anovulatory cycles), but clinical judgment should guide this decision.
External Genitalia Inspection
- Vulvar lesions: Ulcers, masses, condylomata
- Urethral abnormalities: Caruncle, prolapse
- Signs of hyperandrogenism: Clitoromegaly (rare but significant)
- Evidence of trauma: Lacerations, bruising
- Active bleeding: Assess amount, source if visible
Speculum Examination
| Structure | What to Assess | Abnormal Findings |
|---|---|---|
| Vaginal walls | Color, atrophy, lesions, discharge | Atrophy (estrogen deficiency), lesions, abnormal discharge |
| Cervix | Position, size, surface, os, lesions | Polyps, ectropion, cervicitis, suspicious lesions, cervical mass |
| Cervical os | Open or closed, presence of blood or tissue | Open os with tissue suggests miscarriage; polyp at os |
| Source of bleeding | Confirm blood is from cervical os (uterine) versus vaginal or cervical lesion | Important for diagnosis; postcoital bleeding from cervical lesion differs from menstrual bleeding |
| Discharge | Color, consistency, odor | Purulent discharge suggests infection; blood-stained discharge may indicate polyp or malignancy |
Bimanual Examination
| Finding | Technique | Clinical Significance |
|---|---|---|
| Uterine size | Assess between abdominal and vaginal hands; estimate in weeks of pregnancy size | Enlarged: fibroids, adenomyosis, pregnancy. Small: atrophy, hypoestrogenism |
| Uterine contour | Smooth versus irregular | Irregular contour suggests fibroids; uniformly enlarged suggests adenomyosis or pregnancy |
| Uterine mobility | Should move freely | Fixed uterus suggests adhesions, endometriosis, or malignancy |
| Uterine tenderness | Note if palpation elicits pain | Tender: adenomyosis (especially during menses), endometritis, pregnancy complications |
| Cervical motion tenderness | Gently move cervix side to side | Pain suggests pelvic inflammatory disease, ectopic pregnancy, or other acute pathology |
| Adnexal masses | Palpate lateral to uterus bilaterally | Ovarian masses, ectopic pregnancy, tubo-ovarian abscess |
| Adnexal tenderness | Note location and severity | Unilateral: ectopic, ovarian pathology. Bilateral: pelvic inflammatory disease |
Additional Examination Based on Clinical Suspicion
Breast Examination
When indicated: Galactorrhea reported, suspected hyperprolactinemia
What to assess: Nipple discharge (milky versus bloody), breast masses
Significance: Galactorrhea suggests hyperprolactinemia; bloody discharge requires breast imaging
Signs of Hyperandrogenism
Hirsutism: Assess using Ferriman-Gallwey score (face, chest, abdomen, back, arms, thighs)
Acne: Inflammatory acne, especially on jaw and chin
Acanthosis nigricans: Velvety hyperpigmentation in skin folds (neck, axillae, groin)
Androgenic alopecia: Male-pattern hair thinning
Expected Findings by Etiology
| Condition | General Examination | Pelvic Examination | Other Findings |
|---|---|---|---|
| Uterine fibroids | Often normal; may have pallor if anemic | Enlarged, irregular uterus; mobile; usually non-tender | Abdominal mass if large fibroid |
| Adenomyosis | Often normal; pallor if anemic | Uniformly enlarged, globular, “boggy” uterus; tender especially during menses | Often associated with dysmenorrhea |
| Endometrial polyps | Usually normal | Often normal; polyp may be visible at cervical os | May have no abnormal findings |
| Polycystic ovary syndrome | Obesity, acne, hirsutism, acanthosis nigricans | Often normal; ovaries may be slightly enlarged | High BMI, android fat distribution |
| Thyroid dysfunction | Thyroid enlargement or nodules; systemic signs | Usually normal | Signs specific to hypo- or hyperthyroidism |
| Coagulopathy | Bruising, petechiae, pallor | Usually normal; active bleeding may be present | May have bleeding from other sites |
| Anovulatory bleeding | May be normal or show signs of underlying cause (obesity, low BMI, hyperandrogenism) | Often normal | Depends on etiology of anovulation |
| Cervical pathology | Usually normal | Visible lesion on cervix: polyp, ectropion, or suspicious mass | Postcoital bleeding common |
| Pregnancy complications | May show signs of blood loss | Cervix may be open; products of conception may be visible; uterus may be enlarged and tender | Adnexal tenderness or mass with ectopic |
Important Teaching Point
Normal examination is common! Many causes of menstrual change present with entirely normal physical examination findings. In particular:
- Ovulatory dysfunction — Often no abnormal findings unless features of underlying cause (polycystic ovary syndrome, thyroid disease)
- Small endometrial polyps — Not palpable; require imaging for detection
- Small fibroids — May not enlarge uterus sufficiently to be detected on examination
- Coagulopathy — Pelvic examination typically normal
- Endometrial hyperplasia — Cannot be detected on physical examination
A normal physical examination does not exclude significant pathology. Imaging and laboratory investigations are essential components of the workup.
5. Differential Diagnosis
Systematic approach organized by probability, age, and the PALM-COEIN classification
First Step: Always Exclude Pregnancy
In any reproductive-age woman presenting with menstrual changes, pregnancy and pregnancy-related complications must be excluded before proceeding with further differential diagnosis. Obtain a urine or serum beta-hCG regardless of the patient’s stated sexual history or contraceptive use.
Heavy Menstrual Bleeding (Regular Cycles)
Heavy menstrual bleeding with predictable, regular cycles suggests intact ovulation with a structural or hemostatic cause.
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 60-70%) | Uterine leiomyomas (fibroids) | Heavy regular periods, pelvic pressure, enlarged irregular uterus, more common after age 30 | Rapid growth, postmenopausal growth (rare malignant transformation) |
| COMMON | Adenomyosis | Heavy painful periods, dysmenorrhea worsening over time, uniformly enlarged tender uterus | Severe anemia, symptoms not responding to treatment |
| LESS COMMON (approximately 20%) | Endometrial polyps | Heavy periods, intermenstrual bleeding, postmenstrual spotting | Postmenopausal bleeding (increased malignant potential) |
| LESS COMMON | Coagulopathy (von Willebrand disease, platelet disorders) | Heavy bleeding since menarche, family history, other bleeding manifestations | Severe hemorrhage, need for transfusion |
| UNCOMMON BUT SERIOUS (approximately 5-10%) | Endometrial hyperplasia | Risk factors: obesity, anovulation, unopposed estrogen, tamoxifen | Atypical hyperplasia (precancerous) |
| UNCOMMON BUT SERIOUS | Endometrial carcinoma | Postmenopausal bleeding, abnormal bleeding with risk factors, persistent bleeding despite treatment | Any postmenopausal bleeding requires investigation |
Irregular Menstrual Bleeding (Unpredictable Cycles)
Irregular, unpredictable cycles suggest ovulatory dysfunction as the primary mechanism.
Step-by-Step Approach to Irregular Bleeding:
- Step 1: Exclude pregnancy — Always first
- Step 2: Consider life stage — Adolescence and perimenopause commonly have anovulatory cycles
- Step 3: Evaluate for the “Big Four” causes of anovulation — Polycystic ovary syndrome, thyroid dysfunction, hyperprolactinemia, hypothalamic amenorrhea
- Step 4: Assess for structural pathology if bleeding is heavy or persistent
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Polycystic ovary syndrome | 6-12% of reproductive-age women | Irregular cycles, hyperandrogenism (hirsutism, acne), polycystic ovaries on ultrasound, obesity, insulin resistance |
| COMMON | Physiological anovulation (adolescence) | Up to 80% in first 2 years post-menarche | Age less than 2 years from menarche, no other symptoms, normal examination |
| COMMON | Perimenopausal transition | Virtually universal ages 45-55 | Age over 40, vasomotor symptoms, cycle irregularity increasing over time |
| LESS COMMON | Thyroid dysfunction | 2-5% of women | Systemic symptoms: weight change, fatigue, temperature intolerance, constipation/diarrhea |
| LESS COMMON | Hyperprolactinemia | 1-2% of women | Galactorrhea, headache, visual field defects (if pituitary tumor), medication history |
| LESS COMMON | Hypothalamic amenorrhea | Variable | Low body weight, excessive exercise, high stress, restrictive eating, low estrogen symptoms |
| UNCOMMON | Premature ovarian insufficiency | 1% of women under 40 | Age less than 40, irregular then absent periods, vasomotor symptoms, elevated FSH |
| UNCOMMON | Cushing syndrome | Rare | Central obesity, striae, proximal weakness, hypertension, glucose intolerance |
| UNCOMMON | Androgen-secreting tumor | Rare | Rapid onset virilization, very high testosterone, adrenal or ovarian mass |
Amenorrhea (Absent Menstruation)
Primary Amenorrhea
Definition: No menarche by age 15 with normal secondary sexual characteristics, or by age 13 without secondary sexual development
- Anatomical: Müllerian agenesis, imperforate hymen, transverse vaginal septum
- Gonadal dysgenesis: Turner syndrome (45,X)
- Hypothalamic-pituitary: Constitutional delay, Kallmann syndrome
- Androgen insensitivity syndrome
Secondary Amenorrhea
Definition: Absence of menstruation for 3 or more months (or 6 months if previously irregular)
- Pregnancy — Most common cause
- Hypothalamic: Functional hypothalamic amenorrhea, stress, weight loss
- Pituitary: Hyperprolactinemia, Sheehan syndrome
- Ovarian: Premature ovarian insufficiency, polycystic ovary syndrome
- Uterine: Asherman syndrome (intrauterine adhesions)
- Outflow obstruction: Cervical stenosis
Intermenstrual and Postcoital Bleeding
| Category | Condition | Key Features | Investigation Priority |
|---|---|---|---|
| Cervical causes | Cervical ectropion | Common in young women and those on combined oral contraceptives; visible red area around os | Clinical diagnosis; rule out infection |
| Cervical causes | Cervical polyps | Visible at cervical os, bleeds on contact | Remove and send for histology |
| Cervical causes | Cervicitis | Mucopurulent discharge, contact bleeding, associated sexually transmitted infection | Sexually transmitted infection screening |
| Cervical causes | Cervical intraepithelial neoplasia or cervical cancer | Abnormal cervical appearance, persistent postcoital bleeding, abnormal Pap smear history | Colposcopy; urgent if cancer suspected |
| Uterine causes | Endometrial polyps | Intermenstrual spotting, postmenstrual bleeding | Transvaginal ultrasound, saline infusion sonography |
| Iatrogenic | Hormonal contraceptive breakthrough bleeding | First 3 months of use, missed pills, drug interactions | Clinical diagnosis; counsel and observe |
Postmenopausal Bleeding
Critical Point: All Postmenopausal Bleeding Requires Investigation
Any bleeding occurring more than 12 months after the final menstrual period must be investigated to exclude endometrial malignancy. While benign causes are more common, approximately 10% of postmenopausal bleeding is due to endometrial cancer.
| Probability | Condition | Approximate Frequency | Diagnostic Approach |
|---|---|---|---|
| MOST COMMON | Endometrial atrophy | 60-80% | Thin endometrium on ultrasound (less than 4 mm); may not require biopsy if thin |
| LESS COMMON | Endometrial polyps | 10-15% | Focal thickening on ultrasound; hysteroscopy for diagnosis and treatment |
| LESS COMMON | Endometrial hyperplasia | 5-10% | Thickened endometrium; requires biopsy for diagnosis and classification |
| SERIOUS | Endometrial carcinoma | Approximately 10% | Thickened or irregular endometrium; definitive diagnosis requires biopsy |
| OTHER | Cervical pathology, vaginal atrophy, hormone therapy effects | Variable | Speculum examination; consider cervical and vaginal sources |
Anatomical Approach: PALM-COEIN Classification
Structural: PALM
P — Polyp: Endometrial, cervical
A — Adenomyosis: Diffuse or focal
L — Leiomyoma: Submucosal (SM), other (O)
M — Malignancy: Endometrial, cervical; hyperplasia
Non-Structural: COEIN
C — Coagulopathy: von Willebrand, platelet disorders
O — Ovulatory dysfunction: PCOS, thyroid, perimenopause
E — Endometrial: Primary hemostatic/inflammatory disorders
I — Iatrogenic: Medications, IUDs, hormones
N — Not yet classified
Pregnancy-Related
Intrauterine pregnancy: Threatened miscarriage, incomplete miscarriage, molar pregnancy
Ectopic pregnancy: Medical emergency if ruptured
Gestational trophoblastic disease
Postpartum: Retained products, subinvolution
Cervical and Vaginal
Cervical: Polyps, ectropion, cervicitis, CIN, carcinoma
Vaginal: Atrophy, infection, trauma, malignancy
Vulvar: Trauma, infection
Non-gynecological: Urethral, rectal sources
Drug-Induced Menstrual Changes
| Drug or Drug Class | Mechanism | Pattern of Menstrual Change | Management |
|---|---|---|---|
| Anticoagulants (warfarin, DOACs, heparin) | Impaired coagulation cascade | Heavier, prolonged menstrual bleeding | Review indication and INR; consider tranexamic acid; gynecology input |
| Antiplatelet agents (aspirin, clopidogrel) | Impaired platelet function | Increased menstrual blood loss | Assess risk-benefit; hormonal management may help |
| Copper intrauterine device | Local inflammatory response, increased prostaglandins | 30-50% increase in blood loss, longer duration, more dysmenorrhea | NSAIDs for first few cycles; consider switch to hormonal IUD if persistent |
| Progestin-only contraceptives | Endometrial atrophy with fragile vessels | Irregular unpredictable bleeding, especially initially | Counsel about expected pattern; often improves over 3-6 months |
| Combined hormonal contraceptives | Endometrial suppression | Breakthrough bleeding (especially if missed pills), lighter withdrawal bleeds | Review compliance; consider higher estrogen dose if persistent |
| Antipsychotics (risperidone, haloperidol) | Dopamine antagonism causing hyperprolactinemia | Oligomenorrhea, amenorrhea, galactorrhea | Check prolactin; consider switching to prolactin-sparing agent |
| Metoclopramide | Dopamine antagonism | Amenorrhea, galactorrhea with prolonged use | Review need; limit duration of use |
| SSRIs and SNRIs | Serotonin effect on platelet function | Increased menstrual bleeding in some patients | Monitor; may need to switch agents if problematic |
| Tamoxifen | Partial estrogen agonist effect on endometrium | Increased risk of polyps, hyperplasia, and endometrial cancer | Investigate any abnormal bleeding promptly |
| Systemic corticosteroids | Suppression of hypothalamic-pituitary-ovarian axis | Oligomenorrhea, amenorrhea | Usually reversible when steroids reduced |
| Chemotherapy | Gonadotoxicity, hypothalamic-pituitary suppression | Amenorrhea (may be temporary or permanent) | Fertility preservation counseling before treatment if appropriate |
| Herbal supplements (ginseng, dong quai) | Estrogenic or antiplatelet effects | Irregular bleeding, heavier periods | Discontinue and observe |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Heavy regular periods + enlarged irregular uterus | Uterine fibroids | Pelvic ultrasound |
| Heavy painful periods + uniformly enlarged tender uterus | Adenomyosis | Pelvic ultrasound or MRI |
| Irregular cycles + obesity + hirsutism + acne | Polycystic ovary syndrome | Testosterone, LH, FSH, ultrasound |
| Irregular cycles + weight change + fatigue | Thyroid dysfunction | TSH |
| Amenorrhea + galactorrhea + headache | Hyperprolactinemia (pituitary adenoma) | Prolactin level, pituitary MRI if elevated |
| Amenorrhea + low BMI + excessive exercise | Hypothalamic amenorrhea | FSH, LH, estradiol (all low) |
| Heavy bleeding since menarche + easy bruising | von Willebrand disease or platelet disorder | CBC, PT, PTT, von Willebrand panel |
| Intermenstrual spotting + normal examination | Endometrial polyp | Transvaginal ultrasound, saline infusion sonography |
| Postcoital bleeding + visible cervical lesion | Cervical pathology (rule out malignancy) | Colposcopy, cervical biopsy |
| Any postmenopausal bleeding | Endometrial pathology (rule out cancer) | Transvaginal ultrasound, endometrial biopsy |
| Irregular cycles + hot flashes + age over 40 | Perimenopause | Clinical diagnosis; FSH if uncertain |
| Amenorrhea + hot flashes + age under 40 | Premature ovarian insufficiency | FSH (elevated), estradiol (low), repeat to confirm |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
First-Line Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Urine or serum beta-hCG | Exclude pregnancy | Positive or negative | Mandatory in all reproductive-age women regardless of history; serum more sensitive for early pregnancy |
| Complete blood count | Assess for anemia, thrombocytopenia | Hemoglobin, MCV (microcytic in iron deficiency), platelet count | Low hemoglobin confirms impact of bleeding; microcytosis suggests chronic blood loss |
| Ferritin | Assess iron stores | Low ferritin (less than 30 μg/L) confirms iron deficiency | May be low even before hemoglobin drops; ferritin is acute phase reactant (may be falsely normal with inflammation) |
| Thyroid-stimulating hormone (TSH) | Screen for thyroid dysfunction | Elevated (hypothyroidism) or suppressed (hyperthyroidism) | Both hypo- and hyperthyroidism cause menstrual irregularity; simple and cost-effective screen |
Second-Line Investigations Based on Presentation
If Suspecting Structural Pathology (Heavy Regular Bleeding, Pelvic Mass)
First-Line Imaging
- Transvaginal ultrasound: Best initial imaging; assesses uterine size, fibroids, endometrial thickness, ovaries, adnexal masses
- Endometrial thickness interpretation:
- Premenopausal: varies with cycle (up to 16 mm in secretory phase)
- Postmenopausal (not on HRT): greater than 4 mm warrants further investigation
- Postmenopausal (on HRT): greater than 5 mm warrants investigation
Second-Line Imaging
- Saline infusion sonography (SIS): Saline distends cavity to better visualize intracavitary lesions (polyps, submucosal fibroids)
- Hysteroscopy: Direct visualization of uterine cavity; allows diagnosis and treatment of polyps and submucosal fibroids
- Pelvic MRI: Best for mapping fibroids (number, size, location) before surgery; diagnosing adenomyosis
If Suspecting Ovulatory Dysfunction (Irregular Cycles)
Hormonal Assessment
- FSH and LH: Elevated FSH suggests ovarian insufficiency; LH:FSH ratio greater than 2:1 suggests polycystic ovary syndrome (though not diagnostic)
- Estradiol: Low estradiol with elevated FSH confirms ovarian insufficiency; low with low FSH suggests hypothalamic cause
- Prolactin: Elevated levels cause anovulation; if elevated, repeat fasting and consider pituitary imaging
- Total testosterone: Elevated in polycystic ovary syndrome; markedly elevated (greater than 5.2 nmol/L) suggests tumor
- DHEA-S: Elevated suggests adrenal source of androgens
- 17-hydroxyprogesterone: Screen for non-classic congenital adrenal hyperplasia if hyperandrogenic
Timing of Hormone Tests
- FSH, LH, estradiol: Days 2-5 of cycle (early follicular phase) or any time if amenorrheic
- Progesterone: Day 21 (or 7 days before expected period) to confirm ovulation; greater than 10 nmol/L suggests ovulation
- Prolactin: Fasting, morning sample; avoid stress and breast stimulation before test
- Androgens: Morning sample; ideally early follicular phase
If Suspecting Coagulopathy (Heavy Bleeding Since Menarche, Bleeding History)
| Investigation | Purpose | Interpretation |
|---|---|---|
| Complete blood count with platelet count | Assess platelet quantity | Thrombocytopenia (less than 150 × 10⁹/L) may explain bleeding |
| Prothrombin time (PT) and activated partial thromboplastin time (aPTT) | Screen coagulation cascade | Prolonged PT: factor VII deficiency or warfarin; prolonged aPTT: factors VIII, IX, XI, XII deficiency, von Willebrand disease |
| von Willebrand factor antigen (vWF:Ag) | Quantify von Willebrand factor | Less than 30% is diagnostic of von Willebrand disease; 30-50% is borderline |
| von Willebrand factor activity (vWF:RCo or vWF:GPIbM) | Assess functional activity | Low activity with low antigen confirms diagnosis |
| Factor VIII activity | Often low in von Willebrand disease | Low levels correlate with bleeding severity |
| Platelet function testing | Assess platelet function disorders | Consider if platelet count normal but bleeding history suggestive; specialist referral recommended |
Testing Considerations for von Willebrand Disease
von Willebrand factor levels fluctuate and are affected by:
- Blood type: Type O individuals have 25-30% lower levels
- Estrogen: Levels increase with pregnancy and estrogen-containing contraceptives
- Stress and inflammation: Acute phase response increases levels
- Menstrual cycle: May vary through cycle
Repeat testing may be necessary if initial results are borderline or inconsistent with clinical picture.
Endometrial Assessment
Indications for Endometrial Biopsy
- All postmenopausal bleeding (unless endometrium clearly thin on ultrasound)
- Age 45 or older with abnormal uterine bleeding
- Age less than 45 with risk factors: obesity, polycystic ovary syndrome, chronic anovulation, diabetes, tamoxifen use, family history of endometrial or colon cancer
- Failed medical management of abnormal bleeding
- Thickened endometrium on ultrasound (greater than 4 mm postmenopausal; or irregularly thickened in premenopausal)
- Persistent intermenstrual bleeding
| Method | Procedure | Advantages | Limitations |
|---|---|---|---|
| Office endometrial biopsy (Pipelle) | Thin flexible catheter samples endometrium in office without anesthesia | Quick, inexpensive, no anesthesia, 90-98% sensitivity for cancer if adequate sample | May miss focal lesions (polyps); inadequate sample in 10-15%; discomfort |
| Hysteroscopy with directed biopsy | Direct visualization of cavity with targeted sampling | Can visualize and biopsy focal lesions; simultaneous treatment possible | Requires specialized equipment; may need anesthesia; higher cost |
| Dilation and curettage | Surgical dilation of cervix and curettage of endometrium | More complete sampling than Pipelle | Requires anesthesia; still may miss focal lesions; largely replaced by hysteroscopy |
Targeted Investigation Pathways
Polycystic Ovary Syndrome Workup
Rotterdam Criteria (2 of 3 required for diagnosis):
- Oligo- or anovulation (irregular cycles)
- Clinical or biochemical hyperandrogenism
- Polycystic ovaries on ultrasound (12 or more follicles per ovary or ovarian volume greater than 10 mL)
Additional tests to consider: Fasting glucose and insulin (or HbA1c), lipid profile, liver function tests (if considering metformin)
Premature Ovarian Insufficiency Workup
| Investigation | Expected Finding | Notes |
|---|---|---|
| FSH (repeat x2, 4-6 weeks apart) | Greater than 25-40 IU/L (menopausal range) | Must confirm with repeat testing before diagnosis |
| Estradiol | Low (less than 100 pmol/L) | Confirms hypoestrogenic state |
| Karyotype | Screen for Turner syndrome (45,X) and variants | Especially if age less than 30 |
| FMR1 gene testing | Fragile X premutation | Present in 3-15% of premature ovarian insufficiency; implications for family |
| Adrenal antibodies | Autoimmune adrenalitis | If positive, screen for Addison disease |
| Thyroid antibodies, TSH | Associated autoimmune thyroid disease | Common association |
Amenorrhea Workup Algorithm
Stepwise Approach to Secondary Amenorrhea:
- Exclude pregnancy: beta-hCG
- Check TSH and prolactin: Identify thyroid disease and hyperprolactinemia
- Assess estrogen status: FSH and estradiol
- High FSH, low estradiol → Ovarian failure (premature ovarian insufficiency if under 40)
- Low/normal FSH, low estradiol → Hypothalamic or pituitary cause
- Normal FSH, normal estradiol → Likely polycystic ovary syndrome or outflow obstruction
- Progestogen challenge test: If estrogen status unclear
- Withdrawal bleed → Adequate estrogen, anovulation
- No withdrawal bleed → Low estrogen or outflow obstruction
- If suspected outflow obstruction: Pelvic ultrasound, hysteroscopy (Asherman syndrome)
Empiric Treatment Trials as Diagnostic Tools
When Empiric Treatment is Appropriate
In younger women (under 45) with likely anovulatory bleeding, a trial of medical therapy may be both diagnostic and therapeutic:
- Combined oral contraceptives for 3 months: Controls bleeding and regulates cycles; if effective, supports diagnosis of ovulatory dysfunction
- Cyclical progestogens: Medroxyprogesterone 10 mg daily for 10-14 days each month; controls unopposed estrogen effect
- Levonorgestrel intrauterine system: Highly effective for heavy menstrual bleeding; therapeutic trial can avoid need for surgery
Important: Empiric treatment should not replace endometrial assessment in women with risk factors for endometrial pathology or in those over 45 years of age.
Summary: Investigation Pathway by Presentation
| Presentation | First-Line Investigations | Second-Line if Indicated |
|---|---|---|
| Heavy regular cycles | beta-hCG, CBC, ferritin, TSH, transvaginal ultrasound | Coagulation screen if suspected; saline infusion sonography or hysteroscopy for intracavitary lesions |
| Irregular cycles | beta-hCG, CBC, TSH, prolactin, FSH, LH, testosterone | DHEA-S, 17-OHP if hyperandrogenic; estradiol if amenorrheic; pelvic ultrasound |
| Amenorrhea | beta-hCG, TSH, prolactin, FSH, estradiol | Progestogen challenge; pituitary MRI if prolactin elevated; karyotype if premature ovarian insufficiency |
| Intermenstrual bleeding | beta-hCG, STI screen, cervical cytology if due, transvaginal ultrasound | Saline infusion sonography, hysteroscopy, colposcopy if cervical abnormality |
| Postcoital bleeding | Speculum examination, STI screen, cervical cytology | Colposcopy if abnormal cervix or cytology |
| Postmenopausal bleeding | Transvaginal ultrasound (endometrial thickness), endometrial biopsy | Hysteroscopy if biopsy inconclusive or focal lesion suspected |
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways for menstrual change
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Hemodynamically unstable with active bleeding (tachycardia, hypotension, altered consciousness) | EMERGENT | IV access, fluid resuscitation, type and crossmatch, urgent gynecology consult, consider transfusion |
| Positive pregnancy test with bleeding and abdominal pain | EMERGENT | Exclude ectopic pregnancy immediately with ultrasound; surgical emergency if ruptured |
| Severe anemia with symptoms (hemoglobin less than 70 g/L with dyspnea, chest pain, presyncope) | EMERGENT | Admit, transfuse, identify and treat source, urgent gynecology referral |
| Postmenopausal bleeding | URGENT | Expedited workup within 2 weeks; transvaginal ultrasound and endometrial biopsy to exclude malignancy |
| Moderate anemia (hemoglobin 70-100 g/L) with ongoing heavy bleeding | URGENT | Initiate medical management (hormonal, tranexamic acid), iron replacement, expedite workup |
| Suspicious cervical lesion on examination | URGENT | Urgent colposcopy referral; suspected cervical cancer pathway |
| Heavy menstrual bleeding affecting quality of life | SOON | Initiate first-line investigations and medical management; referral if not responding |
| Irregular cycles without heavy bleeding, age under 45 | ROUTINE | Outpatient workup; lifestyle counseling; hormonal management if desired |
Step 2: Classify the Pattern of Menstrual Change
Heavy Regular Cycles
Suggests: Structural cause or coagulopathy
Proceed to: Algorithm A
Irregular Unpredictable Cycles
Suggests: Ovulatory dysfunction
Proceed to: Algorithm B
Absent Menstruation
Suggests: Pregnancy, hypothalamic, pituitary, ovarian, or uterine cause
Proceed to: Algorithm C
Algorithm A: Heavy Regular Menstrual Bleeding
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Enlarged irregular uterus on examination | Uterine fibroids | Confirm with transvaginal ultrasound; assess fibroid location; medical or surgical management based on size, location, symptoms, fertility wishes |
| Uniformly enlarged, tender uterus with dysmenorrhea | Adenomyosis | Confirm with ultrasound or MRI; medical management first-line (LNG-IUS, combined hormonal contraceptives); hysterectomy if refractory and family complete |
| Normal examination, intermenstrual spotting, ultrasound shows focal endometrial thickening | Endometrial polyp | Saline infusion sonography or hysteroscopy; polypectomy is curative |
| Heavy bleeding since menarche, easy bruising, family history of bleeding | von Willebrand disease or other coagulopathy | Coagulation studies and von Willebrand panel; hematology referral; tranexamic acid, desmopressin, hormonal management |
| Normal examination, normal ultrasound, no coagulopathy | Endometrial cause or unexplained heavy menstrual bleeding | Trial of medical management (LNG-IUS most effective); consider endometrial biopsy if over 45 or risk factors |
Algorithm B: Irregular Menstrual Bleeding
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Age less than 2 years from menarche, otherwise healthy adolescent | Physiological anovulation (immature HPO axis) | Reassurance, menstrual diary, consider combined oral contraceptives if bothersome or anemic; screen for coagulopathy if heavy |
| Obesity, hirsutism, acne, oligomenorrhea | Polycystic ovary syndrome | Confirm with Rotterdam criteria; lifestyle modification; metformin if metabolic syndrome; combined oral contraceptives or cyclical progestogens for cycle control; anti-androgens for hirsutism |
| Irregular cycles with weight change, fatigue, temperature intolerance | Thyroid dysfunction | Check TSH; treat underlying thyroid condition; cycles often normalize with treatment |
| Oligomenorrhea or amenorrhea with galactorrhea | Hyperprolactinemia | Check prolactin; if elevated, pituitary MRI; treat cause (medication change, dopamine agonist for prolactinoma) |
| Age over 40, irregular cycles, vasomotor symptoms | Perimenopause | Supportive care; hormonal management for symptoms; endometrial assessment if heavy bleeding or prolonged amenorrhea followed by heavy bleed |
| Age 45 or older with irregular heavy bleeding | Perimenopause BUT must exclude endometrial pathology | Endometrial biopsy before assuming benign cause; transvaginal ultrasound; lower threshold for investigation |
Algorithm C: Amenorrhea
Systematic Approach to Secondary Amenorrhea:
- Pregnancy test: Always first. If positive → obstetric care
- If negative, check TSH and prolactin:
- Abnormal TSH → Treat thyroid disorder
- Elevated prolactin → Pituitary MRI, dopamine agonist if prolactinoma
- If TSH and prolactin normal, check FSH and estradiol:
- High FSH, low estradiol → Ovarian failure (premature ovarian insufficiency if under 40)
- Low/normal FSH, low estradiol → Hypothalamic or pituitary cause (functional hypothalamic amenorrhea, pituitary lesion)
- Normal FSH, normal estradiol → Likely polycystic ovary syndrome or uterine cause
- If uterine cause suspected: Ultrasound, hysteroscopy to assess for Asherman syndrome (intrauterine adhesions)
Decision-Making in Special Populations
Adolescents (Menarche to 19 Years)
| Scenario | Action |
|---|---|
| Irregular cycles within 2 years of menarche, not heavy, no anemia | Reassurance; menstrual diary; review in 6-12 months |
| Heavy bleeding since menarche | Screen for coagulopathy (up to 20% have bleeding disorder); check hemoglobin and ferritin |
| No menarche by age 15 (with breast development) or age 13 (without) | Investigate for primary amenorrhea; karyotype, pelvic ultrasound, hormone profile |
| Irregular heavy cycles with obesity, hirsutism, acne | Evaluate for polycystic ovary syndrome; lifestyle counseling; combined oral contraceptives for cycle control |
Women Seeking Fertility
| Scenario | Action |
|---|---|
| Irregular cycles, desires pregnancy | Confirm ovulatory dysfunction; ovulation induction if anovulatory (clomiphene, letrozole); fertility referral if not conceiving |
| Heavy cycles due to fibroids, desires pregnancy | Assess fibroid location; submucosal fibroids may need removal before conception; medical management not appropriate if trying to conceive |
| Amenorrhea with low estrogen, desires pregnancy | Address underlying cause; fertility referral for ovulation induction or assisted reproduction |
| Premature ovarian insufficiency, desires pregnancy | Fertility counseling; donor oocyte IVF may be only option; spontaneous pregnancy rare but possible |
Perimenopausal Women (Age 40 to Menopause)
Key Principle: Lower Threshold for Investigation
While irregular cycles are expected in perimenopause, the risk of endometrial pathology increases with age. Do not assume all bleeding is due to perimenopause.
- Indications for endometrial biopsy: Age 45 or older with abnormal bleeding; persistent intermenstrual bleeding; heavy prolonged bleeding; bleeding after prolonged amenorrhea
- Indications for ultrasound: All perimenopausal women with abnormal bleeding should have transvaginal ultrasound
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient is bleeding heavily right now | Assess hemodynamic stability; if unstable, IV access, fluids, consider transfusion | High-dose hormonal therapy (combined oral contraceptives or progestogens); tranexamic acid; urgent gynecology if not responding |
| Hemoglobin is critically low (less than 70 g/L) | Admit for transfusion if symptomatic or actively bleeding | Treat cause; iron replacement; consider IV iron for faster repletion |
| Ultrasound shows thickened endometrium in postmenopausal woman | Arrange endometrial biopsy | If biopsy shows hyperplasia or malignancy, refer to gynecology oncology |
| Patient has been trying medical management without improvement | Review compliance and duration of treatment | Ensure adequate trial (3-6 months); consider alternative medical therapy or surgical options; re-evaluate diagnosis |
| Young woman with amenorrhea and low BMI | Screen for eating disorder; assess bone health | Multidisciplinary approach (nutrition, psychology); estrogen replacement for bone protection if prolonged amenorrhea |
| Prolactin is elevated | Review medications (antipsychotics, metoclopramide); repeat fasting if mildly elevated | If persistently elevated greater than 100 μg/L or symptomatic, pituitary MRI |
| Patient wants to avoid hormonal treatment | Discuss non-hormonal options: tranexamic acid, NSAIDs | If structural cause, may need surgical management; address underlying concerns about hormones |
| Adolescent with heavy bleeding and suspected coagulopathy | Full coagulation workup including von Willebrand panel | Hematology referral if confirmed; combined approach with gynecology |
Troubleshooting Refractory Menstrual Symptoms
Ask These Questions When Treatment Is Not Working
- Was the treatment duration adequate? Most hormonal treatments need 3-6 months for full effect
- Was patient compliance good? Missed pills, incorrect timing reduce efficacy
- Is the diagnosis correct? Reconsider differential; may need further investigation
- Are there multiple overlapping causes? Fibroids plus adenomyosis; structural plus ovulatory dysfunction
- Has the patient developed a new condition? Endometrial polyp, new fibroid growth
- Are there drug interactions? Enzyme inducers reduce hormonal contraceptive efficacy
- Is surgical management now indicated? Discuss options: endometrial ablation, myomectomy, hysterectomy
Medical versus Surgical Management Decision Points
| Factor | Favors Medical Management | Favors Surgical Management |
|---|---|---|
| Fertility wishes | Desires future pregnancy (most cases) | Family complete; desires definitive treatment |
| Fibroid size and location | Small, intramural, asymptomatic | Large (greater than 5 cm), submucosal, causing significant symptoms |
| Response to medical therapy | Good response, tolerable side effects | Failed multiple medical treatments |
| Patient preference | Prefers to avoid surgery; willing to use ongoing medication | Desires one-time definitive treatment; does not want ongoing medication |
| Surgical risk | High surgical risk (comorbidities, obesity) | Low surgical risk, otherwise healthy |
| Age and proximity to menopause | Close to menopause; can bridge with medication | Many years from menopause; long-term medication undesirable |
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Always exclude pregnancy first: Regardless of stated sexual history or contraceptive use, obtain a beta-hCG in all reproductive-age women with menstrual changes. Early pregnancy may not be recognized by the patient.
Heavy bleeding since menarche suggests coagulopathy: Up to 20% of adolescents presenting with heavy menstrual bleeding have an underlying bleeding disorder, most commonly von Willebrand disease. Always screen these patients.
Irregular cycles usually mean anovulation: If cycles are unpredictable in timing and flow, think ovulatory dysfunction first. Regular heavy cycles suggest a structural cause or coagulopathy.
The levonorgestrel intrauterine system is remarkably effective: The LNG-IUS reduces menstrual blood loss by 90% or more and should be offered as first-line treatment for heavy menstrual bleeding in most women. It is more effective than oral medications.
Postmenopausal bleeding is cancer until proven otherwise: Approximately 10% of postmenopausal bleeding is due to endometrial cancer. Every case requires investigation with ultrasound and endometrial sampling.
Multiple causes can coexist: A woman may have fibroids AND adenomyosis AND ovulatory dysfunction. Do not stop investigating after finding one abnormality if symptoms are not fully explained.
Fibroid location matters more than size: A small submucosal fibroid (distorting the cavity) causes more bleeding than a large intramural or subserosal fibroid. Always assess location on imaging.
Tranexamic acid is underutilized: This non-hormonal option reduces menstrual blood loss by 40-50% and can be used alongside hormonal treatments. It is taken only during menstruation.
Critical Pitfalls to Avoid
Assuming perimenopausal bleeding is benign: While irregular cycles are expected in perimenopause, the risk of endometrial hyperplasia and cancer increases with age. Women over 45 with abnormal bleeding need endometrial assessment.
Forgetting to check iron stores: Hemoglobin may be normal while ferritin is depleted. Many women with heavy menstrual bleeding have symptomatic iron deficiency (fatigue, cognitive difficulties) before becoming anemic.
Dismissing adolescent heavy bleeding as “normal”: While some irregularity is expected in the first 1-2 years after menarche, heavy bleeding causing anemia or significant life disruption is not normal and warrants investigation, especially for coagulopathy.
Not asking about medications: Many drugs cause menstrual changes. Anticoagulants increase bleeding, antipsychotics cause amenorrhea, and the copper IUD increases menstrual blood loss by 30-50%. A thorough medication history is essential.
Inadequate duration of medical treatment: Hormonal treatments often take 3-6 months to achieve full effect. Irregular bleeding in the first 3 months of progestin-only contraceptives is expected. Do not abandon treatment prematurely.
Missing ectopic pregnancy: Any reproductive-age woman with bleeding and abdominal pain needs a pregnancy test and, if positive, urgent evaluation to exclude ectopic pregnancy. This is a life-threatening emergency.
Relying solely on Pipelle biopsy for focal lesions: Office endometrial biopsy samples only a small portion of the endometrium and may miss polyps or focal hyperplasia. If clinical suspicion is high despite a benign biopsy, proceed to hysteroscopy.
Ignoring quality of life impact: Heavy menstrual bleeding is defined by the patient’s perception that bleeding interferes with their life, not by objective measurement. Take patient concerns seriously even if “numbers” seem acceptable.
Key Takeaways
- First step is always pregnancy test: Exclude pregnancy in all reproductive-age women with menstrual changes before any further workup or treatment.
- Classify the pattern: Heavy regular cycles suggest structural causes; irregular cycles suggest ovulatory dysfunction. This guides investigation and management.
- PALM-COEIN provides structure: Use this classification system to systematically consider structural (Polyp, Adenomyosis, Leiomyoma, Malignancy) and non-structural (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified) causes.
- Age influences differential and workup: Adolescents need coagulopathy screening; reproductive-age women need pregnancy testing; perimenopausal and postmenopausal women need endometrial assessment.
- First-line investigations are simple: Beta-hCG, complete blood count, ferritin, TSH, and transvaginal ultrasound will diagnose or direct further investigation in most cases.
- LNG-IUS is first-line for heavy menstrual bleeding: The levonorgestrel intrauterine system is more effective than oral medications and should be offered to most women with heavy menstrual bleeding.
- Investigate postmenopausal bleeding urgently: All postmenopausal bleeding requires investigation to exclude endometrial malignancy. Expedite ultrasound and endometrial biopsy.
- Consider coagulopathy in adolescents: Up to 20% of adolescents with heavy menstrual bleeding since menarche have an underlying bleeding disorder. Screen proactively.
- Multiple causes can coexist: Finding one cause does not exclude others. If symptoms are not fully explained, continue to investigate.
- Patient preferences matter: Fertility wishes, desire to avoid hormones, and preference for definitive versus ongoing treatment should guide management decisions.
Quick Reference Algorithm
Systematic Approach to Menstrual Change:
- Exclude pregnancy — Beta-hCG in all reproductive-age women
- Assess urgency — Hemodynamic stability, severity of anemia, red flag features
- Classify the pattern — Heavy regular cycles, irregular cycles, or amenorrhea
- Obtain baseline investigations — Complete blood count, ferritin, TSH, transvaginal ultrasound
- Target further investigations — Based on clinical suspicion (hormones for anovulation, coagulation studies if coagulopathy suspected, endometrial biopsy if indicated)
- Consider age and risk factors — Lower threshold for endometrial sampling in women over 45 or with risk factors
- Initiate management — Medical first-line in most cases (LNG-IUS highly effective); surgical options if medical management fails or patient prefers
- Review and reassess — Allow adequate treatment duration (3-6 months); investigate further if not responding
PALM-COEIN Quick Reference
Structural Causes (PALM)
- P — Polyp: Focal endometrial overgrowth; intermenstrual bleeding
- A — Adenomyosis: Endometrium in myometrium; painful heavy periods
- L — Leiomyoma: Fibroids; heavy regular periods; location determines symptoms
- M — Malignancy: Endometrial cancer; postmenopausal bleeding; risk factors
Non-Structural Causes (COEIN)
- C — Coagulopathy: Bleeding disorder; heavy bleeding since menarche
- O — Ovulatory dysfunction: PCOS, thyroid, perimenopause; irregular cycles
- E — Endometrial: Primary hemostatic defect; diagnosis of exclusion
- I — Iatrogenic: Medications, IUDs, hormones
- N — Not yet classified: Does not fit other categories